Inhibition of @entity7 suppresses the in vivo growth of XXXX @entity263 .

@entity1 @entity263 @entity7 @entity19 @entity5 @entity1486
The LNCaP @entity1 @entity263 cell line is androgenand stromal-dependent for in vivo growth. We co-inoculated LNCaP cells with @entity1 fetal fibroblasts, isolated from prostate, bone (male), and lung (male and female) derived from 18- to 22-week-old @entity1 fetal tissue, into non-castrate male @entity19 . Co-inoculation of LNCaP with fetal prostatic fibroblasts resulted in high @entity5 take rates (27 of 30, or 90%) 6 to 8 weeks after subcutaneous co-inoculation. Serum @entity1486 (PSA) values correlated strongly with wet @entity5 weight (r=0.86). The fetal fibroblast enhancement of @entity5 take rates in vivo was neither gender- nor organ-specific. Fetal fibroblast-conditioned medium (CM) did not have a significant proliferative effect on LNCaP cell growth in vitro. Areas of angiogenesis were demonstrable in all @entity5 , with blood vessels arising at the interface between stromal and @entity5 cells. The fetal fibroblasts, but not the LNCaP cells, expressed significant amounts of the mRNA and protein for @entity7 ( @entity7 ). Treatment of @entity5 -bearing animals with neutralizing antibodies to @entity7 resulted in significant @entity5 growth suppression. These findings indicate that @entity7 is an important mediator of stromal-induced enhancement of @entity1 @entity263 cell growth in vivo.
